LFVN / LifeVantage Corporation - SEC-arkiveringar, Årsredovisning, Fullmaktsutlåtande

Exhibit 99.1

Exhibit 99.1 LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2026 Salt Lake City, UT, May 6, 2026, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2026. Third Quarter Fiscal 2026 Summar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-35647 LIFEVANTAGE CORPORATION

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2026 Lifevantage Corporation (Exact name of Registrant as Specified in Its Charter) Delaware 001-35647 90-0224471 (State or Other Jurisdiction of Incorporation) (Commission Fi

INDEPENDENT CONTRACTOR CONSULTANT AGREEMENT

Exhibit 10.1 INDEPENDENT CONTRACTOR CONSULTANT AGREEMENT This Independent Contractor Consultant Agreement (“Agreement”) is entered into as of this the 1st day of May 2026 (the “Effective Date”), by and between Michael Beindorff (hereinafter referred to as “Consultant”), and LifeVantage Corporation, a Delaware corporation based in Lehi, Utah of the USA (“LifeVantage”). 1. Engagement of Services 1.1

LifeVantage Appointing Terrence Moorehead as Chief Executive Officer

Exhibit 99.1 LifeVantage Appointing Terrence Moorehead as Chief Executive Officer Salt Lake City, UT, April 16, 2026, LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Terrence Moorehead as the Company’s new President and

FORM 8-K Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2026 Lifevantage Corp (Exact name of Registrant as Specified in Its Charter) Delaware 001-35647 90-0224471 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Exhibit 10.2 TRANSITION AGREEMENT AND GENERAL RELEASE RECITALS AGREEMENT GENERAL PROVISIONS ACCEPTED AND AGREED:

Exhibit 10.2 TRANSITION AGREEMENT AND GENERAL RELEASE This Transition Agreement and General Release (“Agreement”) is entered into by and between Steven R. Fife (“Employee”) and LifeVantage Corporation, a Delaware corporation (the “Company” or “Employer”) (together the “Parties”) in consideration for and as condition precedent to Employer providing the transition benefits to Employee as set forth b

March 18, 2026

March 18, 2026 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.

LETTER

March 16, 2026 Steven Fife Chief Executive Officer LifeVantage Corporation 3300 Triumph Blvd.

________________________________________ LIFEVANTAGE CORPORATION as Issuer as Trustee Dated as of , 20 Providing for the Issuance of Debt Securities in Series LIFEVANTAGE CORPORATION Reconciliation and tie between the Trust Indenture Act of 1939 and

Exhibit 4.4 INDENTURE between LIFEVANTAGE CORPORATION as Issuer and [TRUSTEE] as Trustee Dated as of , 20 Providing for the Issuance of Debt Securities in Series LIFEVANTAGE CORPORATION Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec. 312(c) 701 Sec. 314(a) 703 (c)(1) 102 (c)(2)

As filed with the Securities and Exchange Commission on March 10, 2026 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 LIFEVANTAGE CORPORATION (E

As filed with the Securities and Exchange Commission on March 10, 2026 Registration No.

Calculation of Filing Fee Tables Form S-3 (Form Type) LifeVantage Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Fo

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) LifeVantage Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common stock, $0.

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026 Announces New $60 Million Share Repurchase Authorization

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2026 Announces New $60 Million Share Repurchase Authorization Salt Lake City, UT, February 4, 2026, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2025.

LifeVantage Announces Planned Retirement of Steve Fife and CEO Succession Plan

LifeVantage Announces Planned Retirement of Steve Fife and CEO Succession Plan SALT LAKE CITY, February 4, 2026 – LifeVantage Corporation® (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health at the cellular level, today announced that after nine years at LifeVantage, Steve Fife, President, Chief Executive Officer and a member of the Board of Directors (the “Board”), has decided to retire in April, 2026.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2026 LIFEVANTAGE CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2026 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2025 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-35647 LIFEVANTAGE CORPORAT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2025 LIFEVANTAGE CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2025 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

As filed with the Securities and Exchange Commission on November 13, 2025

As filed with the Securities and Exchange Commission on November 13, 2025 Registration No.

Calculation of Filing Fee Tables Form S-8 (Form Type) LifeVantage Corporation (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) LifeVantage Corporation (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(4) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(4) Equity Common Stock, par value $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 LIFEVANTAGE CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2026

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2026 Salt Lake City, UT, November 4, 2025, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2025.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-35647 LIFEVANTAGE CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 LIFEVANTAGE CORP

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2025 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin

ARS

LifeVantage Corporation Fiscal Year 2025 Annual Report UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION WASHINGTON,D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35647 LIFEVANTAGE CORPORATIO

1 Insider Trading Policy Amended and Restated on April 29, 2025 Introduction LifeVantage Corporation (referred to herein as “LifeVantage” or the “Company”) is a publicly traded company and is subject to United States securities laws which contain ver

insidertradingpolicy 1 Insider Trading Policy Amended and Restated on April 29, 2025 Introduction LifeVantage Corporation (referred to herein as “LifeVantage” or the “Company”) is a publicly traded company and is subject to United States securities laws which contain very strict prohibitions regarding trading in securities.

SUBSIDIARIES OF LIFEVANTAGE CORPORATION

Exhibit 21.1 SUBSIDIARIES OF LIFEVANTAGE CORPORATION Set forth below is a list of all subsidiaries of LifeVantage Corporation, a Delaware corporation, and the state or country of incorporation of each as of June 30, 2025. Name State or Country of Incorporation Dinng Creative, Inc. Utah Importadora LifeVantage S. de R.L. de C.V. Mexico LFVN Malaysia SDN. BHD. Malaysia LifeLine Nutraceuticals Corpor

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2025

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2025 Salt Lake City, UT, September 4, 2025, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2025.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 LIFEVANTAGE COR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2025 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiz

Evolve Compensation Plan (Hong Kong)

COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS HONG KONG Effective 01 March 2025 ©2024 LifeVantage Hong Kong Limited Suite 2701, 27/F.

Evolve Compensation Plan (Philippines)

COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS PHILIPPINES Effective 01 March 2025 ©2024 Protandim Philippines Corporation • 02 8 395 3355 • www.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-35647 LIFEVANTAGE CORPORATION

Evolve Compensation Plan (Singapore)

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS SINGAPORE Effective 1 March 2025 Welcome 2 activatedLife.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organization)

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025 Salt Lake City, UT, May 6, 2025, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025.

Evolve Compensation Plan (Taiwan)

LIFEVANTAGE獨立顧問獎金計畫 台灣 2025年3月1日下午3時生效 台灣生命優勢有限公司 • 台北市松山區南京東路三段337號11樓C室，郵遞區號10550 • +886(2)5579-8000 lifevantage.

Evolve Compensation Plan (UK), as amended on November 1, 2024

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS UNITED KINGDOM Effective 1 November 2024 Welcome 2 activatedLife.

Evolve Compensation Plan (United States), as amended on November 1, 2024

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS USA Effective November 1, 2024 Welcome 2 activatedLife.

Evolve Compensation Plan (New Zealand), as amended on November 1, 2024

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS NEW ZEALAND Effective 1 November 2024 Welcome 2 activatedLife.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-35647 LIFEVANTAGE CORPORAT

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2025

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2025 Salt Lake City, UT, February 5, 2025, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2024.

Evolve Compensation Plan (Japan)

Evolve ライフバンテージ ライフバンテージの独立コンサルタント向け報酬プランガイド 日本向け 発効日 エボルブ ブックレット 2024年11月1日 Welcome 2 activated人生は、複雑で厄介ですが、それでいて美しい ものです。あっという間に過ぎていくので、一瞬 一瞬を充実させたいと願うものの、日々の生活 やその責任感から、なかなか新たな一歩が踏み 出せないかもしれません。でも私たちは、もっと 自由になって、健やかで幸せな人生を送ってい いのです。 ここにライフバンテージの存在意義がありま す。 当社の製品は、ニュートリゲノミクスによって、 身体が本来持っている、生き生きとした健康を つくり出す力を活用できるように開発されてい ます。 心身ともに最高の自分になったら、その方法をシ ェアしてみませんか？ ライフバンテージは人々の 生活をより良く変える可能性のあるビジネスを、

Evolve Compensation Plan (Mexico), as amended on November 1, 2024

Evolve GUÍA DEL PLAN DE COMPENSACIÓN PARA CONSULTORES INDEPENDIENTES DE LIFEVANTAGE MÉXICO En vigor a partir del 1 de noviembre de 2024 Bienvenido 2 activatedLa vida es complicada, desordenada y hermosa.

Evolve Compensation Plan (EU), as amended on November 1, 2024

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS EUROPEAN UNION Effective 1 November 2024 Welcome 2 activatedLife.

Evolve Compensation Plan (Canada), as amended on November 1, 2024

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS CANADA Effective November 1, 2024 Welcome 2 activatedLife.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2025 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

Evolve Compensation Plan (Australia), as amended on November 1, 2024

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS AUSTRALIA Effective 1 November 2024 Welcome 2 activatedLife.

As filed with the Securities and Exchange Commission on November 21, 2024

As filed with the Securities and Exchange Commission on November 21, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) LifeVantage Corporation (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(4) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(4) Equity Common Stock, par value $0.

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiz

Certificate of Elimination of Series A Junior Participating Preferred Stock of Registrant, filed November 18, 2024

Exhibit 3.1 CERTIFICATE OF ELIMINATION OF SERIES A JUNIOR PARTICIPATING PREFERRED STOCK OF LIFEVANTAGE CORPORATION (Pursuant to Section 151(g) of the General Corporation Law of the State of Delaware) LifeVantage Corporation, a Delaware corporation (the “Company”), certifies as follows: 1. The Certificate of Incorporation (the “Charter”) of the Company, including as amended pursuant to that certain

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number: 001-35647 LIFEVANTAGE CORPORA

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2025

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2025 Salt Lake City, UT, October 29, 2024, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its first fiscal quarter ended September 30, 2024.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2024 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

ARS

LifeVantage Corporation Fiscal Year 2024 Annual Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

Company Policy for the Recovery of Erroneously A

LIFEVANTAGE CORPORATION POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Amended and Restated on November 6, 2023 1.

List of Subsidiaries

Exhibit 21.1 SUBSIDIARIES OF LIFEVANTAGE CORPORATION Set forth below is a list of all subsidiaries of LifeVantage Corporation, a Delaware corporation, and the state or country of incorporation of each as of June 30, 2024. Name State or Country of Incorporation Dinng Creative, Inc. Utah Importadora LifeVantage S. de R.L. de C.V. Mexico LFVN Malaysia SDN. BHD. Malaysia LifeLine Nutraceuticals Corpor

Form of Key Executive Benefits Agreement

1 KEY EXECUTIVE BENEFITS AGREEMENT LifeVantage Corporation (the “Company”) has established this Key Executive Benefits Agreement (the “Agreement”) to attract, motivate and retain certain key executives of the Company.

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2024

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2024 Salt Lake City, UT, August 28, 2024, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2024.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2024 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizat

As filed with the Securities and Exchange Commission on August [28], 2024

As filed with the Securities and Exchange Commission on August [28], 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35647 LIFEVANTAGE CORPORATIO

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) LifeVantage Corporation (Exact name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(4) Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(4) Equity Common Stock, par value $0.

Amended and Restated LifeVantage Corporation 2017 Long-Term Incentive Plan

LIFEVANTAGE CORPORATION 2017 LONG-TERM INCENTIVE PLAN (Adopted on December 6, 2016, Effective on February 16, 2017 and Amended on November 16, 2017, January 19, 2018, September 20, 2018, August 27, 2020, September 19, 2022 and September 21, 2023) SECTION 1.

LifeVantage Welcomes Rajendran Anbalagan to the Board of Directors; Thanks Erin Brockovich for Her Years of Service

LifeVantage Welcomes Rajendran Anbalagan to the Board of Directors; Thanks Erin Brockovich for Her Years of Service SALT LAKE CITY, August 26, 2024 - LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, announced the appointment of Rajendran Anbalagan to the Company’s Board of Directors effective today.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizat

LFVN / LifeVantage Corporation / Radoff Bradley Louis - AMENDMENT NO. 4 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 LifeVantage Corporation (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 53222K205 (CUSIP Number) BRADLEY L. RADOFF 2727

Evolve Compensation Plan (UK)

evolvecompensationplanuk Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS UNITED KINGDOM Effective February 1, 2024 activatedLife.

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2024

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2024 Salt Lake City, UT, May 2, 2024, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2024.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 LIFEVANTAGE CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organization)

Evolve Compensation Plan (Mexico)

evolvecompensationplanme Evolve GUÍA DEL PLAN DE COMPENSACIÓN PARA CONSULTORES INDEPENDIENTES DE LIFEVANTAGE MÉXICO Válido a partir del 1° de febrero de 2024 activadaLa vida.

Evolve Compensation Plan (Canada)

evolvecompensationplanca Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS CANADA Effective February 1, 2024 activatedLife.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-35647 LIFEVANTAGE CORPORATION (Exa

Evolve Compensation Plan (EU)

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS EUROPE Effective February 1, 2024 activatedLife.

Loan Agreement, dated as of April 12, 2024, between LifeVantage Corporation and Bank of America, N.A.

ACTIVE 696074304v9 LOAN AGREEMENT This Loan Agreement (this “Agreement”), dated as of April 12, 2024, is between Bank of America, N.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2024 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizati

, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A.

ACTIVE 696107325v8 SECURITY AND PLEDGE AGREEMENT THIS SECURITY AND PLEDGE AGREEMENT (this “Agreement”) is entered into as of April 12, 2024 among LIFEVANTAGE CORPORATION, a Delaware corporation (the “Borrower”), LIFELINE NUTRACEUTICALS CORPORATION, a Colorado corporation (the “Guarantor”), and such other parties that may become Grantors hereunder after the date hereof (together with the Borrower and the Guarantor, each individually a “Grantor”, and collectively, the “Grantors”), and BANK OF AMERICA, N.

Continuing and Unconditional Guaranty, dated as of April 12, 2024, among LifeVantage Corporation, as Borrower, Lifeline Nutraceuticals Corporation, as Guarantor, and Bank of America, N.A.

ACTIVE 696107200v6 BORROWER: LifeVantage Corporation GUARANTOR: Lifeline Nutraceuticals Corporation CONTINUING AND UNCONDITIONAL GUARANTY 1.

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiz

JOINT FILING AGREEMENT

EX-99.2 2 ex992to13da309076057021524.htm JOINT FILING AGREEMENT Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, par value $

LFVN / LifeVantage Corporation / Radoff Bradley Louis - AMENDMENT NO. 3 TO THE SCHEDULE 13D Activist Investment

SC 13D/A 1 sc13da30907605702152024.htm AMENDMENT NO. 3 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 LifeVantage Corporation (Name of Issuer) Common Stock, par value $0.0001 (Ti

LFVN / LifeVantage Corporation / Sudbury Capital Management, LLC - AMENDMENT NO. 3 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 LifeVantage Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53222K205 (CUSIP Number) Dayton Judd

LifeVantage Appoints Dayton Judd to the Board of Directors Enters into Cooperation Agreement with the Radoff-Sudbury Group Salt Lake City, UT, February 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness c

LifeVantage Appoints Dayton Judd to the Board of Directors Enters into Cooperation Agreement with the Radoff-Sudbury Group Salt Lake City, UT, February 15, 2024 (GLOBE NEWSWIRE) - LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Dayton Judd to the Company’s Board of Directors (the “Board”), effective immediately, in an expansion of the Board.

Cooperation Agreement, by and among the Company, the entities and person listed on Exhibit A thereto, and the entities and person listed on Exhibit B thereto, dated February 14, 2023

Execution Version 1 COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), effective as of February 14, 2024 (the “Effective Date”), is entered into by and among LifeVantage Corporation, a Delaware corporation (the “Company”), the entities and persons listed on Exhibit A hereto (collectively, the “Radoff Parties”) and the entities and persons listed on Exhibit B hereto (collectively, the “Sudbury Parties” and together with the Radoff Parties, the “Stockholder Parties” and each, a “Stockholder Party”).

JOINT FILING AGREEMENT

Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.0001, of LifeVantage Corporation, a Delaware corporation. This

LFVN / LifeVantage Corporation / RENAISSANCE TECHNOLOGIES LLC Passive Investment

SC 13G/A 1 lfvn-13g20231231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* LIFEVANTAGE CORPORATION - (Name of Issuer) Common Stock, par value $0.0001 - (Title of Class of Securities) 53222K205 - (CUSIP Number) December 29, 2023 - (Date of Event Which Requires Filing of this Statement) Check the a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-35647 LIFEVANTAGE CORPORATION (

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2024

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2024 Salt Lake City, UT, January 30, 2024, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2023.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2024 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

GROUP AGREEMENT

EX-99.1 2 ex991to13da209076057111423.htm GROUP AGREEMENT Exhibit 99.1 GROUP AGREEMENT This Agreement (this “Agreement”) is made and entered into as of November 10, 2023 by and among (i) Bradley L. Radoff and The Radoff Family Foundation (collectively, “Radoff”), and (ii) Dayton Judd, Sudbury Capital Fund, LP, Sudbury Holdings, LLC, Sudbury Capital GP, LP and Sudbury Capital Management, LLC (collec

LFVN / Lifevantage Corporation / Radoff Bradley Louis - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 LifeVantage Corporation (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 53222K205 (CUSIP Number) BRADLEY L. RADOFF 2727

November 13, 2023

EX-99.2 3 ex992to13da209076057111423.htm DOCUMENT PRESERVATION NOTICE Exhibit 99.2 O L S H A N 1325 AVENUE OF THE AMERICAS ● NEW YORK, NEW YORK 10019 TELEPHONE: 212.451.2300 ● FACSIMILE: 212.451.2222 EMAIL: [email protected] DIRECT DIAL: 212.451.2257 November 13, 2023 By Email LifeVantage Corporation 3300 North Triumph Boulevard, Suite 700 Lehi, Utah 84043 Attn: Alissa Neufeld General C

LFVN / Lifevantage Corporation / Sudbury Capital Management, LLC - AMENDMENT NO. 2 TO THE SCHEDULE 13D Activist Investment

SC 13D/A 1 sc13da21390000211142023.htm AMENDMENT NO. 2 TO THE SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 LifeVantage Corporation (Name of Issuer) Common Stock, par value $0.0001 per

November 13, 2023

EX-99.2 3 ex992to13da209076057111423.htm DOCUMENT PRESERVATION NOTICE Exhibit 99.2 O L S H A N 1325 AVENUE OF THE AMERICAS ● NEW YORK, NEW YORK 10019 TELEPHONE: 212.451.2300 ● FACSIMILE: 212.451.2222 EMAIL: [email protected] DIRECT DIAL: 212.451.2257 November 13, 2023 By Email LifeVantage Corporation 3300 North Triumph Boulevard, Suite 700 Lehi, Utah 84043 Attn: Alissa Neufeld General C

GROUP AGREEMENT

EX-99.1 2 ex991to13da209076057111423.htm GROUP AGREEMENT Exhibit 99.1 GROUP AGREEMENT This Agreement (this “Agreement”) is made and entered into as of November 10, 2023 by and among (i) Bradley L. Radoff and The Radoff Family Foundation (collectively, “Radoff”), and (ii) Dayton Judd, Sudbury Capital Fund, LP, Sudbury Holdings, LLC, Sudbury Capital GP, LP and Sudbury Capital Management, LLC (collec

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 LIFEVANTAGE CO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organi

Stockholders Re-Elect All Seven LifeVantage Incumbent Directors at Fiscal Year 2024 Annual Meeting Salt Lake City, UT, November 13, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and

lfvnproxyfightoutcomepre Stockholders Re-Elect All Seven LifeVantage Incumbent Directors at Fiscal Year 2024 Annual Meeting Salt Lake City, UT, November 13, 2023 (GLOBE NEWSWIRE) - LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and wellness company with products designed to activate optimal health processes, today announced the final, certified results of its fiscal year 2024 annual meeting of stockholders (the “Annual Meeting”), as provided to the Company by the independent inspector of elections.

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2024

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2024 Salt Lake City, UT, November 9, 2023, LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes, today reported financial results for its first fiscal quarter ended September 30, 2023.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-35647 LIFEVANTAGE CORPORATION

between Sumitomo Mitsui Trust Bank, Limited and LifeVantage Japan

Lease Agreement May 26, 2023 Lessor Sumitomo Mitsui Trust Bank, Limited Lessee LifeVantage Japan Corporation Summary of Terms (1) Lease Property Description of Building Location: 2- 16-4 Konan, Minato-ku, Tokyo Building Name: Shinagawa Grand Central Tower (2) Purpose of Use/ Type of Business Purpose of Use: offices Type of Business: Import, manufacture and sale of health foods and nutritional supplements, cosmetics and quasi-medical products, daily necessities, etc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

LETTER

United States securities and exchange commission logo October 27, 2023 Ryan Nebel Partner, Olshan Frome Wolosky LLP Lifevantage Corp 1325 Avenue of the Americas New York, NY 10019 Re: Lifevantage Corp Definitive Additional Soliciting Materials Filed by Bradley L.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

EXHIBIT 1 - INVESTOR PRESENTATION

OCTOBER 2023 Executing on Our Transformation to Drive Stockholder ValueI N V E S T O R P R E S E N T A T I ON What Is This Proxy Contest About? 2 This proxy contest is about whether half of the independent directors of LifeVantage – nearly all of the Board’s leadership – should be replaced despite the Board’s proactive reformation of the Company’s management team and strategy that has led LifeVant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

EXHIBIT 1 - INVESTOR PRESENTATION

9MJ(FXJKTW'TFWIWTTR (MFSLJFY1NKJ;FSYFLJ 5WJUFWJIG^YMJ7FITKK8ZIGZW^,WTZU 4HYTGJW7FITKK8ZIGZW^,WTZU 1JLFQ)NXHQFNRJW 9MJRFYJWNFQXHTSYFNSJIMJWJNS YMJѦ2FYJWNFQXѧWJUWJXJSYYMJ TUNSNTSXTK'WFIQJ^17FITKK8ZIGZW^(FUNYFQ+ZSI15FSIYMJ TYMJWUFWYNHNUFSYXSFRJINSYMJUWT]^XTQNHNYFYNTS HTQQJHYN[J Q^YMJѦ7FITKK 8ZIGZW^,WTZUѧѦ\JѧTWTZWѦ,WTZUѧFSIFWJGFXJITSUZGQ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide

DFAN14A

ÊÑÌÛ ÌØÛ ÞÔËÛ ÐÎÑÈÇ ÝßÎÜ Ú»´´±© ͬ±½µ¸±´¼»®ô ̸» ο¼±ººóÍ«¼¾«®§ Ù®±«° ±©² ¿°°®±¨·³¿¬»´§ ïîòèû ±º Ô·º»Ê¿²¬¿¹»ô ·¹²¿´·²¹ ±«® ¬®±²¹ ¿´·¹²³»²¬ ©·¬¸ §±«® ·²¬»®»¬ ¿²¼ ¿´´ ݱ³°¿²§ ¬¿µ»¸±´¼»®ò É» ¾»´·»ª» ¬¸¿¬ Ô·º»Ê¿²¬¿¹»Ž ¸»¿´¬¸ °®±¼«½¬ô ¿´» ³±¼»´ ¿²¼ ¹®±©¬¸ ¬®¿¬»¹§ ¸¿ª» ¬¸» °±¬»²¬·¿´ ¬± ½®»¿¬» ·¹²·º·½¿²¬ ª¿´«» ±ª»® ¬¸» ´±²¹ó¬»®³ò λ¹®»¬¬¿¾´§ô ¬¸· °±¬»²¬·¿´ ¸¿ ¾»»² ¸·²¼»®»¼ ±ª»® ¬¸» °¿¬ ¼»½¿¼» ¾§ ݸ¿·®³¿²

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ý Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confide

PRELIMINARY PROXY STATEMENT SUBJECT TO COMPLETION — DATED SEPTEMBER 8, 2023

PRELIMINARY PROXY STATEMENT SUBJECT TO COMPLETION — DATED SEPTEMBER 8, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Certificate of Designation of Series A Junior Participating Preferred Stock of LifeVantage Corporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K filed August 30, 2023).

CERTIFICATE OF DESIGNATION of SERIES A JUNIOR PARTICIPATING PREFERRED STOCK of LIFEVANTAGE CORPORATION Pursuant to Section 151 of the General Corporation Law of the State of Delaware LifeVantage Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 103 thereof, DOES HEREBY CERTIFY: That pursuant t

Rights Agreement, dated as of August 30, 2023, between the Registrant and Computershare Trust Company, N.A., as Rights Agent.

LIFEVANTAGE CORPORATION and COMPUTERSHARE TRUST COMPANY, N.A., as Rights Agent RIGHTS AGREEMENT Dated as of August 30, 2023 TABLE OF CONTENTS Page Section 1. Certain Definitions ................................................................................................ 1 Section 2. Appointment of Rights Agent ............................................................................... 8 Se

Certificate of Designation of Series A Junior Participating Preferred Stock of Registrant

CERTIFICATE OF DESIGNATION of SERIES A JUNIOR PARTICIPATING PREFERRED STOCK of LIFEVANTAGE CORPORATION Pursuant to Section 151 of the General Corporation Law of the State of Delaware LifeVantage Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), in accordance with the provisions of Section 103 thereof, DOES HEREBY CERTIFY: That pursuant t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 90-0224471 (State or other jurisdiction of incorporation) (IRS Employer Identification Number) 3300 Triumph B

Regulation FD Disclosure, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizat

Rights Agreement, dated as of August 30, 2023, between LifeVantage Corporation and Computershare Trust Company, N.A., as Rights Agent (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K filed August 30, 2023).

LIFEVANTAGE CORPORATION and COMPUTERSHARE TRUST COMPANY, N.A., as Rights Agent RIGHTS AGREEMENT Dated as of August 30, 2023 TABLE OF CONTENTS Page Section 1. Certain Definitions ................................................................................................ 1 Section 2. Appointment of Rights Agent ............................................................................... 8 Se

LifeVantage Adopts Limited Duration Stockholder Rights Plan Salt Lake City, UT, August 31, 2023, (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and wellness company with products designed

LifeVantage Adopts Limited Duration Stockholder Rights Plan Salt Lake City, UT, August 31, 2023, (GLOBE NEWSWIRE) - LifeVantage Corporation (Nasdaq: LFVN) (“LifeVantage” or the “Company”), a leading health and wellness company with products designed to activate optimal health processes, today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights plan (the “Rights Plan”).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 001-35647 LIFEVANTAGE CORPORATION (Exact

Evolve Compensation Plan (New Zealand)

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS NEW ZEALAND Effective March 20, 2023 activatedLife.

Evolve Compensation Plan (Japan) in US/English Format

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS JAPAN Effective March 1, 2023 activatedLife.

Form of Key Executive Benefits A

1 KEY EXECUTIVE BENEFITS AGREEMENT LifeVantage Corporation (the “Company”) has established this Key Executive Benefits Agreement (the “Agreement”) to attract, motivate and retain certain key executives of the Company.

Evolve Compensation Plan (Australia)

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS AUSTRALIA Effective March 20, 2023 activatedLife.

Evolve Compensation Plan (United States)

Evolve COMPENSATION PLAN GUIDE FOR INDEPENDENT LIFEVANTAGE CONSULTANTS USA E!ective March 13, 2023 Welcome 2 activatedLife.

Amended and Restated LifeVantage Corporation 2017 Long-Term Incentive Plan

1 LIFEVANTAGE CORPORATION 2017 LONG-TERM INCENTIVE PLAN (Adopted on December 6, 2016, Effective on February 16, 2017 and Amended on November 16, 2017, January 19, 2018, September 20, 2018, August 27, 2020 and September 19, 2022) SECTION 1.

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2023 Declares Special Cash Dividend of $0.40 Per Share

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2023 Declares Special Cash Dividend of $0.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 28, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 LIFEVANTAGE CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizati

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Schedule 14A Information Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Def

LFVN / Lifevantage Corporation / Sudbury Capital Fund, LP - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 LifeVantage Corporation (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 53222K205 (CUSIP Number) Dayton Judd

JOINT FILING AND SOLICITATION AGREEMENT

Exhibit 99.1 JOINT FILING AND SOLICITATION AGREEMENT This Agreement (this “Agreement”) is made and entered into as of August 9, 2023 by and among (i) Bradley L. Radoff and The Radoff Family Foundation (collectively, “Radoff”), (ii) Dayton Judd, Sudbury Capital Fund, LP, Sudbury Holdings, LLC, Sudbury Capital GP, LP and Sudbury Capital Management, LLC (collectively, “Sudbury”) and (iii) Michael Loh

JOINT FILING AND SOLICITATION AGREEMENT

Exhibit 99.1 JOINT FILING AND SOLICITATION AGREEMENT This Agreement (this “Agreement”) is made and entered into as of August 9, 2023 by and among (i) Bradley L. Radoff and The Radoff Family Foundation (collectively, “Radoff”), (ii) Dayton Judd, Sudbury Capital Fund, LP, Sudbury Holdings, LLC, Sudbury Capital GP, LP and Sudbury Capital Management, LLC (collectively, “Sudbury”) and (iii) Michael Loh

LFVN / Lifevantage Corporation / Radoff Bradley Louis - AMENDMENT NO. 1 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 LifeVantage Corporation (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 53222K205 (CUSIP Number) BRADLEY L. RADOFF 2727

POWER OF ATTORNEY

Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Bradley L. Radoff the undersigned’s true and lawful attorney-in-fact to take any and all action in connection with (i) the undersigned’s beneficial ownership of, or participation in a group with respect to, securities of LifeVantage Corporation, a Delaware corporation (the “Company”), di

LifeVantage Extends Stock Repurchase Program Salt Lake City, UT, June 13, 2023, (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes, today announc

lfvn-pressreleasexannoun LifeVantage Extends Stock Repurchase Program Salt Lake City, UT, June 13, 2023, (GLOBE NEWSWIRE) - LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes, today announced that the Company’s Board of Directors has approved an extension to the previously authorized stock repurchase program extending it until December 31, 2026.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 LIFEVANTAGE CORPORA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizatio

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.0001, of LifeVantage Corporation, a Delaware corporation. This

LFVN / Lifevantage Corporation / Radoff Bradley Louis - THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 LifeVantage Corporation (Name of Issuer) Common Stock, par value $0.0001 (Title of Class of Securities) 53222K205 (CUSIP Number) BRADLEY L. RADOFF 2727

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-35647 LIFEVANTAGE CORPORATION (Exa

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2023

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2023 Salt Lake City, UT, May 4, 2023, LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its third fiscal quarter ended March 31, 2023.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 LIFEVANTAGE CORPORATI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2023 LIFEVANTAGE CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 13, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizati

LETTER

United States securities and exchange commission logo April 4, 2023 Steven R. Fife President and Chief Executive Officer LifeVantage Corporation 3300 Triumph Blvd., Suite 700 Lehi, UT 84043 Re: LifeVantage Corporation Registration Statement on Form S-3 Filed March 31, 2023 File No. 333-271061 Dear Steven R. Fife: This is to advise you that we have not reviewed and will not review your registration

April 4, 2023

April 4, 2023 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N.

Form of Indenture with respect to the Securities.

EX-4.4 3 ex44indentureform2023s-3.htm EX-4.4 Exhibit 4.4 INDENTURE between LIFEVANTAGE CORPORATION as Issuer and [TRUSTEE] as Trustee Dated as of , 20 Providing for the Issuance of Debt Securities in Series LIFEVANTAGE CORPORATION Reconciliation and tie between the Trust Indenture Act of 1939 and the Indenture Trust Indenture Act Section Indenture Section Sec. 310(a)(1) 607 (a)(2) 607 (b) 608 Sec.

As filed with the Securities and Exchange Commission on March 31, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 LIFEVANTAGE CORPORATION (E

As filed with the Securities and Exchange Commission on March 31, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) LifeVantage Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Security Type Security Class Title (1) Fee Calculation Rule Amount Registered (2) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (2) Fee Rate Amount of Registration Fee Equity Common stock, $0.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 LIFEVANTAGE CORPOR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizati

Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiz

Letter to the Securities and Exchange Commission from WSRP, LLC, dated February 16, 2023

GDSVF&H\8762231.1 Exhibit 16.1 February 16, 2023 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K dated February 16, 2023. We agree with the statements made in response to that Item insofar as they relate to our Firm. Very truly yours, /s/ WSRP, LLC WSRP, LLC

LFVN / LifeVantage Corp / RENAISSANCE TECHNOLOGIES LLC Passive Investment

SC 13G/A 1 lfvn-13g20221231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* LIFEVANTAGE CORPORATION - (Name of Issuer) Common Stock, par value $0.0001 - (Title of Class of Securities) 53222K205 - (CUSIP Number) December 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the a

LFVN / LifeVantage Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01308-lifevantagecorp.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Lifevantage Corp. Title of Class of Securities: Common Stock CUSIP Number: 53222K205 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-35647 LIFEVANTAGE CORPORATION (

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2023

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2023 Salt Lake City, UT, February 2, 2023, LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its second fiscal quarter ended December 31, 2022.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 18, 2023 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organ

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-35647 LIFEVANTAGE CORPORATION

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2023

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2023 Salt Lake City, UT, November 2, 2022, LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its first fiscal quarter ended September 30, 2022.

30, 2022 by and between Zions Bank and the Company.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEF 14A 1 proxystatementfy2023.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

LFVN / LifeVantage Corp / Sudbury Capital Fund, LP - SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 LIVEVANTAGE CORPORATION (Name of Issuer) Common Stock, Par Value $0.0001 Per Share (Title of Class of Securities) 53222K205 (CUSIP Number) Dayton Judd Sudbury Capital Fund, LP 136 Oak Trail Coppell, TX 75019 972-304-5000 (Name, Address and Telephone Number of Person Author

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2022

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2022 Salt Lake City, UT, August 23, 2022, LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its fourth quarter and full fiscal year ended June 30, 2022.

LifeVantage Sales Compensation Plan

SALES COMPENSATION PLAN HIGHLIGHTS ? UNITED STATES OF AMERICA (1) EFFECTIVE MAY 5, 2020 *PV = Product Volume.

Description of Capital Stock

EX-4.2 2 ex42descriptionofcapitalst.htm EX-4.2 Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General LifeVantage Corporation (“we,” “us,” and “our”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.0001 par value per share. The following information describes our capital stock, as well as certain provisions of our certific

Amended and Restated LifeVantage Corporation 2017 Long-Term Incentive Plan

1 LIFEVANTAGE CORPORATION 2017 LONG-TERM INCENTIVE PLAN (Adopted on December 6, 2016, Effective on February 16, 2017 and Amended on November 16, 2017, January 19, 2018, September 20, 2018, and August 27, 2020) SECTION 1.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2022 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 001-35647 LIFEVANTAGE CORPORATION (Exact

List of Subsidiaries

Exhibit 21.1 SUBSIDIARIES OF LIFEVANTAGE CORPORATION Set forth below is a list of all subsidiaries of LifeVantage Corporation, a Delaware corporation, and the state or country of incorporation of each as of June 30, 2021. Name State or Country of Incorporation Dinng Creative, Inc. Utah Importadora LifeVantage S. de R.L. de C.V. Mexico LFVN Malaysia SDN. BHD. Malaysia LifeLine Nutraceuticals Corpor

Code of Business Conduct and Ethics

Message from the President & CEO This year has been a very different one both globally and at LifeVantage.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 23, 2022 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizat

Forms of Key Executive Benefits Package

-1- KEY EXECUTIVE BENEFIT PACKAGE LifeVantage has established this Key Executive Benefit Package to attract, motivate and retain certain key executives of the company.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 3, 2022 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organization)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-35647 LIFEVANTAGE CORPORATION (Exa

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2022 Initiates first quarterly dividend of $0.03 per common share

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2022 Initiates first quarterly dividend of $0.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizatio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiz

LifeVantage Appoints Cindy Latham to Board of Directors

LifeVantage Appoints Cindy Latham to Board of Directors Salt Lake City, UT, February 17, 2022, (GLOBE NEWSWIRE) - LifeVantage Corporation (Nasdaq:LFVN) today announced the appointment of Cindy Latham to the Company's Board of Directors.

LFVN / LifeVantage Corp / RENAISSANCE TECHNOLOGIES LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* LIFEVANTAGE CORPORATION - (Name of Issuer) Common Stock, par value $0.0001 - (Title of Class of Securities) 53222K205 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

LFVN / LifeVantage Corp / VANGUARD INDEX FUNDS - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Lifevantage Corp. Title of Class of Securities: Common Stock CUSIP Number: 53222K205 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R

LFVN / LifeVantage Corp / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Lifevantage Corp. Title of Class of Securities: Common Stock CUSIP Number: 53222K205 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ R

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2022

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2022 Salt Lake City, UT, February 1, 2022, LifeVantage Corporation (Nasdaq: LFVN) today reported financial results for its second fiscal quarter ended December 31, 2021.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2022 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-35647 LIFEVANTAGE CORPORATION (

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2021 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiz

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2022 Revenue of $53.2 Million Reiterates Guidance

LifeVantage Announces Financial Results for the First Quarter of Fiscal 2022 Revenue of $53.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-35647 LIFEVANTAGE CORPORATION

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

Key Employee Benefits Package by and between

EX-10.2 3 lfvnkeyexecutivebenefit.htm EX-10.2 -1- KEY EXECUTIVE BENEFIT PACKAGE LifeVantage has established this Key Executive Benefit Package to attract, motivate and retain certain key executives of the company. An employee is considered a Key Executive upon the recommendation of the CEO and approval by the Company's Compensation Committee. The components of the Key Executive Benefit Package are

Offer Letter by and between

September 17, 2021 Carl Aure [email protected] Dear Carl, LifeVantage Corporation (the ?Company?), is pleased to offer you a position as Chief Financial Officer reporting directly to our President & CEO. We trust that your knowledge, skills and experience will be among our most valuable assets. ? Salary: Annual gross starting salary of $350,000 paid in installments by direct deposit. ? Performance

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2021 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

LifeVantage Appoints Carl Aure as Chief Financial Officer

LifeVantage Appoints Carl Aure as Chief Financial Officer Salt Lake City, UT, October 25, 2021, (GLOBE NEWSWIRE) - LifeVantage Corporation (Nasdaq:LFVN) today announced the appointment of Carl Aure as Chief Financial Officer.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Prox

Code of Business Conduct and Ethics

Message from the President & CEO This year has been a very different one both globally and at LifeVantage.

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2021 Revenue of $220 million for Fiscal 2021 Fourth Quarter Adjusted EPS Increased 10.7% Year over Year

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2021 Revenue of $220 million for Fiscal 2021 Fourth Quarter Adjusted EPS Increased 10.

List of Subsidiaries

Exhibit 21.1 SUBSIDIARIES OF LIFEVANTAGE CORPORATION Set forth below is a list of all subsidiaries of LifeVantage Corporation, a Delaware corporation, and the state or country of incorporation of each as of June 30, 2021. Name State or Country of Incorporation Dinng Creative, Inc. Utah Importadora LifeVantage S. de R.L. de C.V. Mexico LFVN Malaysia SDN. BHD. Malaysia LifeLine Nutraceuticals Corpor

Amended and Restated LifeVantage Corporation 2017 Long-Term Incentive Plan

1 LIFEVANTAGE CORPORATION 2017 LONG-TERM INCENTIVE PLAN (Adopted on December 6, 2016, Effective on February 16, 2017 and Amended on November 16, 2017, January 19, 2018, September 20, 2018, and August 27, 2020) SECTION 1.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended June 30, 2021 ? TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number: 001-35647 LIFEVANTAGE CORPORATION (Exact

Form of Key Executive Benefits Package

-1- KEY EXECUTIVE BENEFIT PACKAGE LifeVantage has established this Key Executive Benefit Package to attract, motivate and retain certain key executives of the company.

Compensation Plan

SALES COMPENSATION PLAN HIGHLIGHTS ? UNITED STATES OF AMERICA (1) EFFECTIVE MAY 5, 2020 *PV = Product Volume.

Description of Capital Stock

Exhibit 4.2 DESCRIPTION OF CAPITAL STOCK General LifeVantage Corporation (?we,? ?us,? and ?our?) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended - our common stock, $0.0001 par value per share. The following information describes our capital stock, as well as certain provisions of our certificate of incorporation and amended and restated b

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 12, 2021 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizat

LFVN / LifeVantage Corp / BlackRock Inc. Passive Investment

us53222k2050071021.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) LIFEVANTAGE CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 53222K205 - (CUSIP Number) June 30, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

Key Employee Benefits Package by and between Matthew Cooley and LifeVantage Corporation dated May

- Doc ID: 05e1880a12776c9b7a68d56db4d8c28a8b7a524d - Doc ID: 05e1880a12776c9b7a68d56db4d8c28a8b7a524d - Doc ID: 05e1880a12776c9b7a68d56db4d8c28a8b7a524d - Doc ID: 05e1880a12776c9b7a68d56db4d8c28a8b7a524d - Doc ID: 05e1880a12776c9b7a68d56db4d8c28a8b7a524d - Doc ID: 05e1880a12776c9b7a68d56db4d8c28a8b7a524d - Doc ID: 05e1880a12776c9b7a68d56db4d8c28a8b7a524d - Doc ID: 05e1880a12776c9b7a68d56db4d8c28a8b7a524d - 04 / 29 / 2021 04 / 29 / 2021 Doc ID: 05e1880a12776c9b7a68d56db4d8c28a8b7a524d - Doc ID: 05e1880a12776c9b7a68d56db4d8c28a8b7a524d Audit Trail Title File Name Document ID Audit Trail Date Format Status Key Executive Benefits Agreement Key Executive Benefits Agreement.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organization

Offer Letter by and between Matthew Cooley and LifeVantage Corporation dated May

? ? ? ? ? ? ? ? ? ? ? ? 04 / 29 / 2021 Doc ID: c8117190435e8a587a7e8b09a26040a20f396f62 Audit Trail Title File Name Document ID Audit Trail Date Format Status Offer Letter Offer Letter.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2021 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organizati

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2021 Revenue of $51.6 Million Third Quarter Adjusted EPS Increased 53.8% Year over Year

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2021 Revenue of $51.

Amended and Restated Key Executive Benefit Package between the Company and Steven R. Fife dated January 31, 2021

EX-10.2 3 sfifeexecutivebenefitspa.htm EX-10.2 GDSVF&H\5569757.3 AMENDED AND RESTATED KEY EXECUTIVE BENEFIT PACKAGE LifeVantage has established this Key Executive Benefit Package to attract, motivate and retain certain key executives of the company. You are considered a Key Executive upon execution of this agreement. The components of the Key Executive Benefit Package are included below. 1. Positi

Change in Terms Agreement dated April 1, 2021 by and between Zions Bank and the Company

CEO Offer Letter between the Company and Steven R. Fife dated January 31, 2021

GDSVF&H\5569755.1 LIFEVANTAGE CORPORATION 3300 TRIUMPH BLVD LEHI, UTAH 84043 January 31, 2021 Steven R. Fife Dear Steve, LifeVantage Corporation (the ?Company?) is pleased to offer you the role of President and Chief Executive Officer of the Company on the following terms: 1. Position. Your title will be President and Chief Executive Officer. Until a new Chief Financial Officer is appointed, you w

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-35647 LIFEVANTAGE CORPORATION (Exa

SC 13G/A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* LIFEVANTAGE CORPORATION - (Name of Issuer) Common Stock, par value $0.0001 - (Title of Class of Securities) 53222K205 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Lifevantage Corp. Title of Class of Securities: Common Stock CUSIP Number: 53222K205 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Lifevantage Corp. Title of Class of Securities: Common Stock CUSIP Number: 53222K205 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2021 Revenue of $59.0 Million, Up 7.6% Sequentially Second Quarter Adjusted EBITDA Increased 12.6% Steven R. Fife Appointed President & CEO

LifeVantage Announces Financial Results for the Second Quarter of Fiscal 2021 Revenue of $59.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED DECEMBER 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 001-35647 LIFEVANTAGE CORPORATION (

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2021 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiza

LifeVantage Announces Appointment of Chief Executive Officer Steven R. Fife Named President, CEO & Director

EX-99.2 3 exhibit992pressrelease.htm EX-99.2 LifeVantage Announces Appointment of Chief Executive Officer Steven R. Fife Named President, CEO & Director Salt Lake City, UT, February 2, 2021, (GLOBE NEWSWIRE) - LifeVantage Corporation (Nasdaq:LFVN) announced today that its Board of Directors has named Steven Fife as President and Chief Executive Officer. Mr. Fife’s appointment is effective immediat

SC 13G/A

us53222k2050012921.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) LIFEVANTAGE CORP - (Name of Issuer) Common Stock - (Title of Class of Securities) 53222K205 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to w

- S-8

As filed with the Securities and Exchange Commission on January 11, 2021 Registration No.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 LIFEVANTAGE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-35647 90-0224471 (State or other jurisdiction of incorporation or organiz